Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors (MYTHIC)
Фаза 1 исследования безопасности, фармакокинетики, фармакодинамики и предварительной клинической активности RP-6306 отдельно или в комбинации с RP-3500 у пациентов с запущенными солидными опухолями
The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Подробное описание
Phase 1/1b, multi-center, open-label, dose-escalation study to:
- Evaluate the safety profile and MTD of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib when administered orally to establish the recommended Phase 2 dose and schedule
- Characterize the PK and pharmacodynamics of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib
- Assess preliminary anti-tumor activity associated with lunresertib alone and in combination with RP-3500 or in combination with zedoresertib
This study was previously posted by Repare Therapeutics. In September 2025, sponsorship of the trial was transferred to Debiopharm International S.A
Expanded Access Status: There is no expanded access program available for the investigational products in this study at this time.
Тип исследования
Тип исследования
Регистрация (Оцененный)
Регистрация
Фаза
Фаза
- Фаза 1
Контакты и местонахождение
Контакты исследования
Контакты исследования
- Имя: Debiopharm International S.A
- Номер телефона: +41 21 321 01 11
- Электронная почта: clinicaltrials@debiopharm.com
Места учебы
-
-
-
Copenhagen, Дания
- Рекрутинг
- #4001, Rigshospitalet - Blegdamsvej
-
-
-
-
-
Madrid, Испания, 28027
- Еще не набирают
- Clinica Universidad de Navarra
-
Madrid, Испания, 28050
- Рекрутинг
- Hospital Universitario HM Sanchinarro
-
Madrid, Испания, 28040
- Рекрутинг
- START Madrid. Hospital Fundación Jimenez Diaz
-
Navarra, Испания, 31008
- Еще не набирают
- Clinica Universidad de Navarra
-
-
-
-
Ontario
-
Toronto, Ontario, Канада, M5G 1X8
- Завершенный
- #2002, The Hospital for Sick Children
-
Toronto, Ontario, Канада, M5G 2C1
- Рекрутинг
- #2001, Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Канада, H4A 3J1
- Завершенный
- #2003, The Research Institute of the McGill University Health Centre
-
-
-
-
-
London, Соединенное Королевство, W1G 6AD
- Рекрутинг
- #3003, Sarah Cannon Research Institute
-
-
-
-
California
-
Los Angeles, California, Соединенные Штаты, 90095
- Завершенный
- # 1019, UCLA, Westwood Cancer Center
-
San Francisco, California, Соединенные Штаты, 94158
- Рекрутинг
- #1025, University of California San Francisco
-
-
Connecticut
-
New Haven, Connecticut, Соединенные Штаты, 06520
- Рекрутинг
- #1012, Yale
-
-
Florida
-
Jacksonville, Florida, Соединенные Штаты, 32224
- Рекрутинг
- #1017, Mayo Clinic
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02215
- Рекрутинг
- #1002, Dana Farber Cancer Institute
-
-
Michigan
-
Grand Rapids, Michigan, Соединенные Штаты, 49503
- Рекрутинг
- #1023, START Midwest
-
-
Minnesota
-
Rochester, Minnesota, Соединенные Штаты, 55902
- Рекрутинг
- #1016, Mayo Clinic
-
-
Missouri
-
St Louis, Missouri, Соединенные Штаты, 63130
- Рекрутинг
- #1011, Washington University
-
-
New York
-
New Hyde Park, New York, Соединенные Штаты, 11042
- Рекрутинг
- #1032, Northwell Health Cancer Institute
-
New York, New York, Соединенные Штаты, 10065
- Рекрутинг
- #1004, Memorial Sloan Kettering Cancer Institute
-
New York, New York, Соединенные Штаты, 10032
- Завершенный
- #1008, Columbia University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19104
- Завершенный
- #1010, University of Pennsylvania
-
-
Rhode Island
-
Providence, Rhode Island, Соединенные Штаты, 02903
- Рекрутинг
- #1007, Rhode Island Hospital
-
Providence, Rhode Island, Соединенные Штаты, 02903
- Рекрутинг
- #1030, Women & Infants Hospital of Rhode Island
-
-
Texas
-
Houston, Texas, Соединенные Штаты, 77030
- Рекрутинг
- #1001, The University of Texas M.D. Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Соединенные Штаты, 84112
- Рекрутинг
- #1013, The University of Utah
-
-
Virginia
-
Charlottesville, Virginia, Соединенные Штаты, 22903
- Рекрутинг
- #1027, University of Virginia
-
-
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Male or female and ≥12 years-of-age at the time of informed consent.
- Lansky performance status ≥50% for patients ≤16 years of age, or ECOG score of 0, 1, (or 2 for module 1) for patients >16 years of age.
- Locally advanced or metastatic resistant or refractory solid tumors.
- Patients <18 years of age must weigh at least 40 kg.
- Submission of available tumor tissue at screening or willingness to have a biopsy performed if safe and feasible
- Next generation sequencing (NGS) report obtained in a CLIA-certified or equivalent laboratory demonstrating eligible tumor biomarker.
- CCNE1 amplification (non-equivocal) as determined by either a tumor or plasma NGS test, or FISH
- FBXW7 deleterious mutations identified by either a tumor or plasma NGS test
- PPP2R1A deleterious mutations identified by either a tumor or plasma NGS test
- Measurable disease as per RECIST v1.1. For certain modules, patients with prostate cancer or ovarian cancer that have non-measurable disease but have elevated tumor markers (PSA or CA-125, respectively) can also be eligible
- Ability to swallow and retain oral medications.
- Acceptable hematologic and organ function at screening.
- Negative pregnancy test (serum) for women of childbearing potential (WOCBP) at Screening.
- Resolution of all toxicities of prior therapy or surgical procedures.
- Any prior radiation must have been completed at least 7 days prior to the start of study drugs, and patients must have recovered from any acute adverse effects prior to the start of study treatment.
Exclusion Criteria:
- Chemotherapy or small molecule antineoplastic agent given within 21 days or <5 half-lives, whichever is shorter, prior to first dose of study drug.
- History or current condition, therapy, or laboratory abnormality that might confound the study results or interfere with the patient's participation for the full duration of the study treatment.
- Patients who are pregnant or breastfeeding.
- Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the participating patient's safety.
- Major surgery within 4 weeks prior to first dose of lunresertib.
- Uncontrolled, symptomatic brain metastases.
- Uncontrolled hypertension.
- Certain prior anti-cancer therapy
- Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Экспериментальный: Phase 1: Lunresertib Single-Agent, Dose Escalation and Food-effect Study
Patients receive lunresertib orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified. |
Oral PKMYT1 Inhibitor |
|
Экспериментальный: Phase 1: Lunresertib in combination with RP-3500, Dose Escalation Study
Patients receive lunresertib with RP-3500 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified. |
Oral PKMYT1 Inhibitor Oral ATR Inhibitor |
|
Экспериментальный: Phase 1: Lunresertib in combination with Zedoresertib, Dose Escalation Study
Patients receive lunresertib with zedoresertib orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified. |
Oral PKMYT1 Inhibitor Oral WEE1 Inhibitor
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Safety and Tolerability of lunresertib either in monotherapy or in combination with RP-3500 or with Zedoresertib in patients with eligible advanced solid tumors
Временное ограничение: Up to 90 days after last administration of study intervention
|
Assessed by treatment-emergent adverse events (TEAEs), physical examinations (PEs), safety laboratory assessments, electrocardiograms (ECGs), and vital sign measurements |
Up to 90 days after last administration of study intervention
|
|
To define the MTD of lunresertib monotherapy, and determine a recommended Phase 2 dose (RP2D) and preferred schedule
Временное ограничение: Up to 90 days after last administration of study intervention
|
Assessed by the incidence of Dose-limiting toxicities (DLTs) and the incidence and severity of cumulative safety data |
Up to 90 days after last administration of study intervention
|
|
To define the MTD of lunresertib in combination with RP-3500 or in combination with Zedoresertib, and determine a recommended Phase 2 dose (RP2D) and preferred schedule
Временное ограничение: Up to 90 days after last administration of study intervention
|
Assessed by the incidence of dose-limiting toxicities (DLTs) and the incidence and severity of cumulative safety data |
Up to 90 days after last administration of study intervention
|
|
The relative bioavailability of lunresertib capsule formulation as compared to lunresertib tablet formulation in the fasted state
Временное ограничение: Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
|
Assessed by the plasma concentrations of lunresertib with calculation of pharmacokinetic (PK) parameters including maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), area under the plasma concentration-time curve (AUC) , for both formulations in the fasted state. |
Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
|
|
The effect of food on the PK of tablet formulation of lunresertib when administered in fed conditions compared to administration under fasted conditions
Временное ограничение: Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
|
Assessed by the plasma concentrations of lunresertib with calculation of the ratio of PK parameters (e.g., Cmax and AUC) between the tablet formulation under fasted and fed state. |
Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
|
|
To assess the safety and tolerability of lunresertib tablets in combination with RP-3500, confirm the MTD of lunresertib tablets in combination with RP-3500, and determine a RP2D and preferred schedule
Временное ограничение: Up to 90 days after last administration of study intervention
|
Assessed by DLTs, TEAEs, safety laboratory assessments, the incidence of DLTs and the incidence and severity of cumulative safety data |
Up to 90 days after last administration of study intervention
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
The plasma concentrations of lunresertib monotherapy (capsule formulation) in the fasted and fed states
Временное ограничение: Up to 90 days after last administration of study intervention
|
Assessed by the plasma concentrations of lunresertib with calculation of maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), minimum observed plasma concentration (Cmin), area under the plasma concentration-time curve (AUC), elimination half-life (t1/2), and other parameters as appropriate |
Up to 90 days after last administration of study intervention
|
|
To assess the relationship between pharmacodynamic biomarkers and PK of lunresertib at different dose levels and/or schedules
Временное ограничение: Up to 90 days after last administration of study intervention
|
Assessed by evaluation of biomarkers in pre- and on-treatment biopsies, and circulating tumor DNA (ctDNA) dynamics during treatment |
Up to 90 days after last administration of study intervention
|
|
The plasma concentrations of lunresertib and RP-3500 when dosed in combination
Временное ограничение: Up to 90 days after last administration of study intervention
|
Assessed by the plasma concentrations of lunresertib and RP-3500 with calculation of maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), minimum observed plasma concentration (Cmin), area under the plasma concentration-time curve (AUC), elimination half-life (t1/2), and other parameters as appropriate for each analyte |
Up to 90 days after last administration of study intervention
|
|
To assess preliminary anti-tumor activity achieved with lunresertib monotherapy, lunresertib in combination with RP-3500 or lunresertib in combination with Zedoresertib
Временное ограничение: Through Study Completion, an average of 1 year
|
Measured by best percent change in tumor size from baseline, objective response rate (ORR), overall response rate, tumor marker response, duration of response (DOR), clinical benefit rate (CBR), progression-free survival (PFS). |
Through Study Completion, an average of 1 year
|
|
To assess the safety and anti-tumor effects of lunresertib capsule + RP-3500
Временное ограничение: Through Study Completion, an average of 1 year
|
As measure by TEAEs, safety laboratory assessments, Best percent change in tumor size from baseline, ORR, overall response rate, DOR, CBR, tumor marker response, PFS |
Through Study Completion, an average of 1 year
|
|
To further characterize the PK of lunresertib tablets and assess preliminary anti-tumor
Временное ограничение: Through Study Completion, an average of 1 year
|
Measured by Plasma concentrations of lunresertib with calculation of Cmax, Tmax, AUC, elimination t1/2, and other PK parameters as appropriate, Best percent change in tumor size from baseline, ORR, overall response rate, DOR, CBR, tumor marker response, PFS |
Through Study Completion, an average of 1 year
|
Соавторы и исследователи
Спонсор
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Начало исследования
Первичное завершение (Оцененный)
Первичное завершение
Завершение исследования (Оцененный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- Debio 0123-106
- RP-6306-01 (Другой идентификатор: Repare Therapeutics)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .